All In Biotech

Investigational drug · Phase 3

Cebranopadol

Also called: TRN-228

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pain, Acute Pain, Chronic Pain.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

2 still active

All registered trials

14

Any phase or sponsor naming "Cebranopadol"

First trial start

2024

Jul 18, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cebranopadol", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pain
  • Acute Pain
  • Chronic Pain
  • Opioid Withdrawal (Disorder)
  • Opioid Use Disorder

Approved drugs for the same conditions: Opioid use disorder · Acute pain · Psychiatry · Pain and anesthesia

Largest trials

Live from ClinicalTrials.gov: studies naming "Cebranopadol" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 64 on PubMed

Also in development for Pain

  • Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain

  • CT001Phase 31 trial

    Cessatech A/S · Pain

  • MR-107A-02Phase 31 trial

    Viatris Specialty LLC · Acute Pain, Post Operative Pain, Pain

  • SRP-001Phase 21 trial

    South Rampart Pharma, Inc. · Acute Pain, Postoperative Pain, Pain

  • YZJ-4729Phase 21 trial

    Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.